Krystal Biotech (KRYS) Cash & Current Investments (2016 - 2026)

Krystal Biotech has reported Cash & Current Investments for 11 years, with the latest figure at $845.6 million in Q2 2026.

• Cash & Current Investments for Q2 2026 came in at $845.6 million, up 24.0% year-over-year; the trailing twelve-month figure through Jun 2026 was $845.6 million (up 24.0% YoY), and the FY2025 annual result was $827.8 million, up 38.54% from the prior year.
• Cash & Current Investments climbed to $845.6 million in Q2 2026, from $823.4 million in the prior quarter.
• Over five years, Cash & Current Investments peaked at $845.6 million in Q2 2026 and troughed at $350.4 million in Q1 2023.
• A 5-year average of $575.9 million and a median of $560.8 million in 2023 frame the typical range for Cash & Current Investments.
• The widest annual swing landed in 2023, when Cash & Current Investments dropped 19.38%; it then soared 53.62% in 2024.
• A 5-year view of Cash & Current Investments shows it stood at $379.2 million in 2022, then soared by 40.35% to $532.2 million in 2023, then grew by 12.28% to $597.5 million in 2024, then jumped by 38.54% to $827.8 million in 2025, then gained by 2.16% to $845.6 million in 2026.
• Per Business Quant data, the three most recent Cash & Current Investments figures were $845.6 million in Q2 2026, $823.4 million in Q1 2026, and $827.8 million in Q4 2025.